On the occasion of International Women’s Day, Prime Minister, Justin Trudeau, committed to “provide $650 million in funding to address gaps in sexual and reproductive health and rights in the world’s poorest and most vulnerable communities.” “Reproductive health” is a code-name for having access to affordable methods of birth control. In a recent interview with The Canadian Press, Monsef said ...
Maryam Monsef, Minister of Status of Women, along with Anita Vandenbeld, Member of Parliament for Ottawa West-Nepean announced on March 6, 2017 that Planned Parenthood Ottawa is receiving $285,000 for a three-year project to improve services for women in the Ottawa area who are “experiencing gender-based violence, in particular, violence related to sexual and reproductive coercion.”
Conservative Leadership Candidate and Saskatoon-University MP Brad Trost called on the Trudeau Government, today, to reverse its decision to make an initial contribution of $20 million to a Dutch government-initiated global abortion fund, and to embargo any additional funding for abortion. Trost also asked all Conservative leadership candidates to support his call for a cancellation of funding.
Millions of people use melatonin as a sleep aid and for jet lag. A study by the University of Guelph, published this week in the Journal of Clinical Sleep Medicine, tested 30 melatonin supplements produced under 16 brand names and sold in grocery and drug stores.
On February 15, 2017 the Montreal Heart Institute announced the opening of the very first electrophysiology laboratory (EP Lab) equipped with robotic and magnetic navigation and dedicated to congenital heart diseases in Canada.
MedReleaf, a licensed producer (LP) of medical cannabis that has recently received Health Canada approval to sell cannabis capsules, announced on February 16, 2017 that it is providing same-day delivery to patients in the Toronto Greater Area (GTA).
BTG International Canada Inc., part of global specialist healthcare company BTG (LSE: BTG), announced on January 26, 2017 the Canadian commercial launch of Varithena™ (polidocanol injectable foam), a drug/device combination product used to treat varicose veins.